DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Peripheral Artery Disease (PAD) , historical and forecasted epidemiology as well as the Peripheral Artery Disease (PAD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Peripheral Arterial Disease Market with DelveInsight’s In-Depth Report @ Peripheral Arterial Disease Market Size
Key Takeaways from the Peripheral Arterial Disease Market Report
Stay ahead in the Peripheral Arterial Disease Therapeutics Market with DelveInsight’s Strategic Report @ Peripheral Arterial Disease Market Outlook
Peripheral Arterial Disease Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Peripheral Arterial Disease epidemiology trends @ Peripheral Arterial Disease Prevalence
Peripheral Artery Disease Marketed Drugs
XARELTO is an oral anticoagulant for the treatment and prevention of blood clots. In combination with aspirin, it is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO can cause bleeding, which can be serious and may lead to death, as it is a blood thinner medicine (anticoagulant) that lowers blood clotting. In June 2022, the Ministry of Health, Labour and Welfare in Japan approved XARELTO (2.5 mg twice daily, used in combination with aspirin 81–100 mg once daily) to treat patients with PAD after revascularization.
ZONTIVITY is indicated for reducing thrombotic cardiovascular events in patients with a history of MI or with PAD. ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and UCR. In May 2014, Merck received US FDA approval for ZONTIVITY to treat patients with PAD
Emerging Peripheral Artery Disease Drugs
Critical limb ischemia (CLI) is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (hands, feet, and legs). CLI is the advanced form of peripheral arterial disease (PAD) caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque. LSTA12 (also known as Honedra and CLBS12 in Japan) is an experimental regenerative medicine to prevent the serious adverse consequences of CLI and Buerger’s disease by improving blood flow in the affected limb. It is CD34+ cell therapy intended to administer by Intramuscular route, 20 injections in the target limb in a single treatment.
ACP-01, Hemostemix’s lead clinical candidate, is an autologous cell therapy to treat critical limb ischemia (CLI) in patients facing amputation. ACP-01 consists of cells derived from the patient’s blood and modified with Hemostemix’s technology that forms new blood vessels. These cells, known as angiogenic cell precursors, or ACPs, secrete growth factors and cytokines that support the formation of blood vessels through vasculogenesis and angiogenesis. Factors secreted by ACPs also facilitate the recruitment of additional progenitor cells to promote the healing of damaged tissues. When these cells are injected into the dying leg muscle of the same patient with critical limb ischemia, they support the regeneration of new small blood vessels and may prevent amputations.
Get In-Depth Knowledge on Peripheral Arterial Disease Market Trends and Forecasts with DelveInsight @ Peripheral Arterial Disease Treatment Market
Peripheral Artery Disease Market Outlook
Peripheral Artery Disease (PAD) presents various limb-related complications, including intermittent claudication, ischemic rest pain, ulcers, gangrene, and functional impairment. Comprehensive medical treatment involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise, and smoking cessation. Treatment options include lifestyle changes, medication, endovascular and surgical interventions, and emerging therapies like gene and cell therapy. Despite available treatments, PAD is often undertreated compared to coronary artery disease.
Peripheral Arterial Disease Treatment Market
Critical Limb Ischemia (CLI) treatment aims to relieve pain, restore blood flow, and preserve limb function. Strategies include endovascular and surgical revascularization, with therapeutic angiogenesis using gene and cell therapies showing promise. The goals for CLI management are pain relief, healing of lesions, prevention of amputations, and improvement of quality of life and survival. An interdisciplinary approach is essential, with monitoring and managing cardiovascular risk factors being crucial for all PAD patients.
Unlock Strategic Insights with DelveInsight’s Comprehensive Peripheral Arterial Disease Market Report @ Peripheral Arterial Disease Market Drivers and Barriers
Scope of the Peripheral Arterial Disease Market Report
Table of Content
1 Key Insights
2 Report Introduction
3 Peripheral Artery Disease (PAD) Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Executive Summary of Peripheral Artery Disease (PAD)
6 Key Events
7 Disease Background and Overview: Peripheral Artery Disease (PAD)
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Peripheral Artery Disease (PAD) : Seven Major Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/case-study/in-licensing-opportunity